Raybow PharmaScience's headquarters is located in a pharmaceutical production zone in Linhai, Taizhou City in Zhejiang Province, China. Construction began in 2008 and the facility now covers approximately 120,000 square meters, with 1500 employees. Raybow has passed official audits from the USFDA, CFDA and AIFA/PMDA in recent years. Raybow is a leader in green chemical production and manufacturing. Our Taizhou and Suzhou sites have advanced environmental protection treatment systems. This includes a complete set of waste solutions to treat waste liquids, solids and gas. Our equipment allows us to reuse and recirculate certain chemicals used in Pharmaceutical production after they are treated, going a long way to minimize our impact on the environment. Our R&D team is resourceful and has multi-field experienced from our international team of scientists. The team has 400 people and growing, who provide our customers with professional solutions for CDMO projects. Raybow's team is committed to the research and development of new pharmaceutical technology, especially in the area of flow chemistry, high-end fluorine chemistry, asymmetric chiral synthesis, glycosides and biological enzyme technology. Raybow has manufacturing sites in both Taizhou and Suzhou in China. Raybow has 2 modern R&D facilities in China - Hangzhou (opened Spring 2019) and Taizhou which opened in March 2020. Both facilities feature the latest in lab equipment and ample space. In 2019 Raybow added manufacturing and R&D facilities in the United States with the acquisition of PharmAgra Labs. (Now Raybow USA, Inc.) We have business offices in Copenhagen, Denmark and Munich Germany serving Europe as Santa Barbara, California and Princeton, New Jersey which serves the North American pharmaceutical market.